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We used data from 765 cases and 564 controls in the population-based Australian Breast Cancer Family Study to investigate
whether, in women under the age of 40, the profile of risk factors differed between breast cancer subtypes defined by joint oestrogen
and progesterone receptor status. As hypothesised, no significant differences were found.
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It has been postulated that joint oestrogen (ER) and progeste-
rone receptor (PR) status might define aetiologically distinct
subtypes of breast cancer (Potter et al, 1995). The ERþPRþ
subtype predominates in western countries (64–68% in
postmenopausal women) (Thorpe, 1988; Potter et al, 1995), but
is less common in Japanese women (29%) (Nomura et al, 1992).
Neoplasms in women with a germline BRCA1 mutation tend
to be ER  (Phillips, 2000). The pattern of age-specific incidence
rates, according to the joint ER/PR status, was similar in
Danish women up to the age of 43 years, but differed distinctly
thereafter (Yasui and Potter, 1999). This suggests that, if hormone
receptor status is related to aetiology, such a relationship may
be restricted to older women and not be evident in those under the
age of 40 years.
Of published reports on ER or PR status and breast cancer
risk, only three were population-based studies that examined
differences in risk factor profile for the breast cancer subtypes
ERþPRþ,E R þPR ,E R  PRþ, and ER PR . One was
restricted to postmenopausal women (Potter et al, 1995),
a second, predominantly to women over the age of 40 years
(Huang et al, 2000), and the third to women aged 20–44 years
(Britton et al, 2002). We used data from the Australian
Breast Cancer Family Study (ABCFS), a population-based case–
control–family study comprising women with breast cancer
diagnosed before the age of 40 years and controls, to investigate
whether, in that age group, the profile of risk factors differed
between breast cancer subtypes defined by joint ER/PR
status. Based on the findings in Danish women (Yasui and Potter,
1999), we hypothesised that there would be no difference in this
age group.
MATERIAL AND METHODS
The study was carried out in Melbourne, Victoria, and Sydney,
New South Wales, during 1992–1999 (Hopper et al, 1994, 1999;
McCredie et al, 1998). All participants provided written informed
consent prior to participation in the study, which was approved by
the human research ethics committees of the University of
Melbourne and the Cancer Councils of Victoria and New South
Wales.
Cases were identified from the population-based Victorian and
New South Wales cancer registries (to which notification of all
cancer diagnoses is mandatory), and comprised all women living
in the metropolitan areas of Melbourne and Sydney who were aged
less than 40 years at the diagnosis of a histologically confirmed
first primary cancer of the breast (ICD-9 174). Recruitment began
with a letter to the attending doctor, requesting permission to
approach the woman. If permission was granted, a letter to the
woman sought her participation. Of 1208 eligible cases, 856 (71%)
agreed to participate. Reasons for nonparticipation included: death
(2% of total eligible); refusal by the attending doctor (8%) or the
woman (14%); nonresponse by the attending doctor (1%) or the
woman (1%); and the woman having moved and unable to be
located (3%).
Potential controls were women aged less than 40 years and living
in the metropolitan areas of Melbourne and Sydney, who were
selected from the electoral roll (to which adult registration is
compulsory in Australia) using proportional random sampling
based on the expected age distribution of the cases. Of 913 eligible
controls, 600 (66%) agreed to participate, 27% refused and 8% did
not respond.
Participation by cases and controls included a face-to-face
interview in the subject’s home. The two questionnaires covered:
(a) demographic and ethnic background; height; weight; medical
history; reproductive factors; and use of oral contraceptives,
hormone replacement therapy, tobacco, and alcohol and (b) family
history of breast and other cancers. In the period 1992–1995,
participation was restricted to cases and controls who could speak Received 6 May 2003; revised 1 August 2003; accepted 6 August 2003
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yEnglish, while in the period 1996–1999 non-English speakers were
also included.
We obtained both ER and PR status of the tumour for 694 (81%)
participating cases (92% of women diagnosed in 1996–1999; 72%
of those diagnosed in 1992–1995) – 87 through immunohisto-
chemical testing (described in Armes et al, 1999) of tumour tissue
held by the ABCFS, 405 from the histopathology report held at the
cancer registry, and 202 through a written request to the pathology
laboratory that issued the diagnostic histopathology report. ER/PR
status was determined using methods that were immunohisto-
chemical (64%), biochemical (34%) or unknown (2%).
For homogeneity, women known to have a deleterious germline
mutation in either BRCA1 or BRCA2 were excluded. Germline
testing has to date identified 42 cases with a deleterious mutation
in either BRCA1 or BRCA2; a full description of the methods and
extent of mutation testing can be found in Dite et al (2003).
For ease of interpretation, women of ‘Asian descent’ were
excluded, as they differ from ‘western’ women not only with
respect to their pattern of ER/PR subtypes (see above) but also in
the magnitude of their risk of breast cancer. ‘Asian descent’ was
defined as having any grandparent with a southeast Asian ethnic
background (those reported here were Chinese, Japanese, Malay-
sian, Vietnamese, Korean, Filipino and Thai); 50 cases and 36
controls were of ‘Asian descent’. One case of ‘Asian descent’
carried a mutation. Thus, 765 cases (618 with known ER/PR status)
and 564 controls were used in the analyses below.
Statistical analysis
Polytomous logistic regression models were used to estimate
breast cancer risk in five groups defined by ER/PR status
(ERþPRþ,E R þPR ,E R  PRþ,E R  PR , and either ER or
PR unknown) in relation to the following known or suspected risk
factors: family history of breast cancer reported in a first-degree
relative (no, yes); height (o163cm, X163cm); body mass index
(BMI; o23, X23; 1 year before diagnosis (cases) or interview
(controls)); age at menarche (o13 years, X13 years); parous (no,
yes); number of live births (0, 1, 2, X3); age at first live birth (o25
years, X25 years, for parous women only); and whether oral
contraceptives had ever been used (no, yes). Cut-points were
chosen to be consistent with Potter et al (1995) if feasible or, when
this resulted in markedly uneven groups, were based on the
distribution in controls. Differences in proportions, means and
odds ratios were evaluated by unconditional logistic regression,
analysis of variance, and the likelihood ratio test, respectively,
using STATA software.
RESULTS
The mean age at diagnosis of the 765 cases was 34.9 years (s.d. 3.6),
with no difference in age between the five groups defined by ER/PR
status (P¼0.3). Among the 564 controls, the mean age at
recruitment was 33.7 years (s.d. 4.4). Cases with known and
Table 1 Risk of breast cancer
a defined by ER/PR subtype in Australian women under the age of 40 years according to risk factor
ER+PR+ ER+PR  ER PR+ ER PR  ER? &/or PR? Control
N¼323 OR (95% CI)
c N¼34 OR (95% CI) N¼80 OR (95% CI) N¼181 OR (95% CI) N¼147 OR (95% CI) N¼564 LRT
b
11 relative with breast cancer
Yes 9% 12% 8% 11% 9% 4%
Yes (ref: No) 2.5 (1.4–4.6) 3.4 (1.1–11) 1.8 (0.6–4.8) 3.4 (1.8–6.4) 2.2 (1.1–4.5) P¼0.8
Height
X163 59% 62% 70% 59% 58% 55% P¼0.3
X163 (ref: o163) 1.2 (0.9–1.6) 1.3 (0.6–2.7) 1.8 (1.0–3.1) 1.3 (0.9–1.8) 1.4 (0.9–2.1)
Body mass index
X23 43% 50% 46% 50% 51% 46% P¼0.5
X23 (ref: o23) 0.9 (0.7–1.2) 1.2 (0.6–2.3) 1.0 (0.6–1.6) 1.1 (0.8–1.5) 1.3 (0.9–1.3)
Age at menarche
X13years 60% 65% 62% 53% 60% 63%
X13years (ref: o13) 0.8 (0.6–1.1) 0.9 (0.5–1.8) 0.8 (0.5–1.3) 0.6 (0.4–0.9) 0.9 (0.6–1.3) P¼0.5
Ever use of oral contraceptives
Yes 93% 91% 96% 92% 91% 91%
Yes (ref: No) 1.1 (0.7–1.9) 1.3 (0.4–4.0) 1.1 (0.5–2.5) 0.9 (0.5–1.6) 1.0 (0.6–1.9) P¼0.6
Ever had live birth
Yes 69% 74% 73% 72% 73% 65%
Yes (ref: No) 1.0 (0.7–1.4) 1.7 (0.7–4.4) 1.4 (0.8–2.6) 1.0 (0.7–1.6) 1.0 (0.6–1.7) P¼0.9
Age at first live birth
d
X25 67% 64% 69% 56% 56% 59%
X25 (ref: o25) 1.7 (1.1–2.5) 1.7 (0.7–4.3) 1.3 (0.7–2.5) 0.9 (0.6–1.4) 1.0 (0.6–1.7) P¼0.2
Number of live births
1 13% 24% 28% 17% 14% 12%
1 (ref: 0) 1.1 (0.7–1.7) 2.6 (0.9–7.1) 2.6 (1.3–5.2) 1.3 (0.8–2.3) 1.1 (0.6–2.1)
2 35% 26% 28% 36% 38% 29%
2 (ref: 0) 1.0 (0.7–1.5) 1.3 (0.5–3.8) 1.0 (0.5–2.0) 1.0 (0.6–1.7) 1.1 (0.7–1.9)
X3 21% 24% 18% 19% 21% 24% P¼0.8
X3 (ref: 0) 1.0 (0.5–1.2) 1.4 (0.5–4.3) 0.9 (0.4–1.9) 0.8 (0.4–1.3) 0.8 (0.4–1.4)
aPolytomous logistic regression adjusted for study centre, study period, reference age, highest completed education level, country of birth, marital status, affected first-degree
relative, height, body mass index, age at menarche, number of live births, and ever used oral contraceptives.
bLikelihood ratio test.
cOdds ratio with 95% confidence interval.
dParous women only.
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yunknown ER/PR status were similar with respect to educational
level (P¼0.4), marital status (P¼0.5), and whether or not they
had been born in Australia (P¼0.1).
Among the 618 tumours with known ER/PR status, the
distribution of ER/PR subtypes was 53% ERþPRþ,6 %
ERþPR , 13% ER PRþ, and 29% ER PR , and there was no
difference in this distribution between tumours diagnosed in
1992–1995 and those diagnosed in 1996–1999 (P¼0.1).
Table 1 gives the proportion of women by risk factor in each ER/
PR-defined group, and shows that the odds ratios for breast cancer
according to risk factor did not differ between the ER/PR subtypes
(0.2oPo0.9). The inclusion of women of ‘Asian descent’, and/or
those with a BRCA1 or BRCA2 mutation, and the exclusion of
women with unknown ER/PR status, made essentially no
difference to this finding.
DISCUSSION
As hypothesised, this population-based study in non-Asian
Australian women under the age of 40 years found, with or
without excluding cases known to carry a germline mutation in
BRCA1 or BRCA2, no evidence that the effects of any of the major
established risk factors differ for breast cancers defined by joint ER
and PR status. This lack of heterogeneity in disease in young
women accords with the analysis of Yasui and Potter (1999), who
applied the age-specific distribution of ER/PR subtypes seen in
tumours of 3359 cases (of all ages) in the Danish Breast Cancer
Cooperative Group to the national Danish age-specific breast
cancer incidence rates (age was the only risk factor examined in
their analysis).
The Danish data support the suggestion that ER/PR receptor
status might define aetiologically distinct subtypes of breast cancer
in older women. While two other population-based studies of
breast cancer have claimed evidence for some differences in risk
factor profile according to joint ER/PR receptor status (Potter et al,
1995; Huang et al, 2000), they should perhaps be viewed as
hypothesis-generating analyses, given that their findings were
based on multiple comparisons, had nominal P-values of marginal
significance, and some comparisons lacked statements about the
statistical significance of observed differences in odds ratios. A
third study, of early onset disease, found, as we did, no clear
support for aetiologically distinct subtypes (Britton et al, 2002).
Neither BRCA1 or BRCA2 mutation carriers nor women of Asian
descent had been excluded from these studies.
Our null finding must be tempered by considerations of
statistical power – we could have missed modest differences in
risk factor profiles. Each of the previous studies (Potter et al, 1995;
Huang et al, 2000; Britton et al, 2002) had similarly limited power.
To resolve these issues, there is a need for bigger or combined
studies with careful consideration of age at diagnosis, ethnic
background, and the status of deleterious germline mutations in
known susceptibility genes.
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